Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01025934 |
Recruitment Status :
Completed
First Posted : December 4, 2009
Last Update Posted : December 4, 2009
|
Sponsor:
University of Campania "Luigi Vanvitelli"
Collaborator:
Napoli CTO Hospital
Information provided by:
University of Campania "Luigi Vanvitelli"
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to evaluate the role, the safety and the effectiveness of Intravitreal Bevacizumab injections as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Proliferative Diabetic Retinopathy | Drug: Bevacizumab Other: sham | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Primary Purpose: | Treatment |
Official Title: | Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy |
Resource links provided by the National Library of Medicine

Drug Information available for:
Bevacizumab
Arm | Intervention/treatment |
---|---|
Active Comparator: 7 days |
Drug: Bevacizumab |
Active Comparator: 20 days |
Drug: Bevacizumab |
Sham Comparator: sham |
Other: sham |
Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- vitreous haemorrhage
- tractional retinal detachment
- active proliferative diabetic retinopathy.
Exclusion Criteria:
- neovascular glaucoma
- cataract
- combined traction and rhegmatogenous RD
No Contacts or Locations Provided
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: | NCT01025934 |
Other Study ID Numbers: |
IVBDRNA |
First Posted: | December 4, 2009 Key Record Dates |
Last Update Posted: | December 4, 2009 |
Last Verified: | December 2009 |
Additional relevant MeSH terms:
Retinal Diseases Diabetic Retinopathy Eye Diseases Diabetic Angiopathies Vascular Diseases Cardiovascular Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases |
Bevacizumab Antineoplastic Agents, Immunological Antineoplastic Agents Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors |